Back to Search Results
Image Place holder

Hugo Fernandez, MD

Chair, Malignant Hematology and Cellular Therapy at Memorial Healthcare System

 
Specialty: Hematology
Sub Specialty: Hematology, Medical Oncology
Program: Malignant Hematology and Cellular Therapy at Memorial Healthcare System

Call 1-888-663-3488

Call 1-888-663-3488


Locations:
Overview

Cancer Focus: Leukemia, Myelodysplastic Syndromes (MDS)

Dr. Hugo Fernandez is Chair and Medical Director of Moffitt Malignant Hematology and Cellular Therapy at Memorial Healthcare System in Pembroke Pines. He is also a professor of oncology at the University of South Florida Morsani College of Medicine. Dr. Fernandez’s clinical and research interests include molecular therapies for acute myeloid and lymphoid disorders, developing new transplant conditioning regimens for myeloid leukemia and expanding transplantation for elderly patients. Dr. Fernandez received his medical degree from the University of Florida College of Medicine. He served a residency in internal medicine and was chief resident at the University of Miami/Jackson Memorial Medical Center, where he also completed a fellowship in hematology/oncology. Dr. Fernandez then pursued additional training as an academic fellow in blood and marrow transplantation at the University of Texas/MD Anderson Cancer Center. Prior to coming to Moffitt, Dr. Fernandez was an associate professor of clinical medicine and director of the bone marrow transplant program at the University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center. Dr. Fernandez has been published in numerous peer-reviewed journals and is an ad hoc reviewer for various professional journals. He is a member of several medical organizations and serves as a board member for the Foundation for the Accreditation of Cell Therapy and for the Moffitt Medical Group.


Education & Training

Board Certification:

  • Internal Medicine - Hematology
  • Internal Medicine - Medical Oncology

Fellowship:

  • University of Miami/Jackson Memorial Medical Center - Hematology/Oncology
  • University of Texas, MD Anderson Cancer Center - BMT, Division of Hematology

Residency:

  • University of Miami/Jackson Memorial Medical Center - Internal Medicine

Medical School:

  • University of Florida College of Medicine - MD
Awards
Start Year: 2014 End Year: Physician of the Year Award, Sponsor: Moffitt Cancer Center
Video Profile
Participating Trials

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Medeiros BC, Othus M, Tallman MS, Sun Z, Fernandez HF, Rowe JM, Lazarus HM, Appelbaum FR, Luger SM, Litzow MR, Erba HP. The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900). Leuk Res. 2019 Mar.78:29-33. Pubmedid: 30673620. Pmcid: PMC6615032.
  • Khimani F, McDonald GB, Shulman HM, Betts B, Locke F, Fernandez H, Anasetti C, Pidala J. Hepatic veno-occlusive disease following sirolimus-based immune suppression. Bone Marrow Transplant. 2019 Jan.54(1):85-89. Pubmedid: 29895929.
  • Repaczki-Jones R, Hrnicek AK, Heissenbuttel A, Devine S, Fernandez H, Anasetti C. Defining Competency to Empower Blood and Marrow Transplant and Cellular Immunotherapy Quality Management Professionals in Healthcare. Biol Blood Marrow Tr. 2019 Jan.25(1):179-182. Pubmedid: 30138698.
  • Pidala J, Beato F, Kim J, Betts B, Jim H, Sagatys E, Levine JE, Ferrara JL, Ozbek U, Ayala E, Davila M, Fernandez HF, Field T, Kharfan-Dabaja MA, Khaira D, Khimani F, Locke FL, Mishra A, Nieder M, Nishihori T, Perez L, Riches M, Anasetti C. IL-12/IL-23p40 neutralization blocks Th1/Th17 response after allogeneic hematopoietic cell transplantation. Haematologica. 2018 Mar.103(3):531-539. Pubmedid: 29242294. Pmcid: PMC5830373.
  • Barata A, Gonzalez BD, Sutton SK, Small BJ, Jacobsen PB, Field T, Fernandez H, Jim HS. Coping strategies modify risk of depression associated with hematopoietic cell transplant symptomatology. J Health Psychol. 2018 Jun.23(8):1028-1037. Pubmedid: 27106092. Pmcid: PMC5509511.
  • Murthy HS, Sheets K, Kumar A, Nishihori T, Mina A, Chavez JC, Ayala E, Field T, Mathews J, Locke F, Perez L, Betts BC, Khimani F, Miladinovic B, Tsalatsanis A, Ochoa-Bayona JL, Alsina M, Fernandez H, Pidala J, Anasetti C, Kharfan-Dabaja MA. Hypoalbuminemia at Day +90 Is Associated with Inferior Nonrelapse Mortality and Overall Survival in Allogeneic Hematopoietic Cell Transplantation Recipients: A Confirmatory Study. Biol Blood Marrow Tr. 2018 Feb.24(2):400-405. Pubmedid: 29032266.
  • Ganzel C, Sun Z, Cripe LD, Fernandez HF, Douer D, Rowe JM, Paietta EM, Ketterling R, O'Connell MJ, Wiernik PH, Bennett JM, Litzow MR, Luger SM, Lazarus HM, Tallman MS. Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience. Am J Hematol. 2018 Aug.93(8):1074-1081. Pubmedid: 29905379. Pmcid: PMC6699929.
  • Betts BC, Pidala J, Kim J, Mishra A, Nishihori T, Perez L, Ochoa-Bayona JL, Khimani F, Walton K, Bookout R, Nieder M, Khaira DK, Davila M, Alsina M, Field T, Ayala E, Locke FL, Riches M, Kharfan-Dabaja M, Fernandez H, Anasetti C. IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation. Haematologica. 2017 May.102(5):948-957. Pubmedid: 28104702. Pmcid: PMC5477614.
  • Khimani F, Kim J, Chen L, Dean E, Rizk V, Betts B, Nishihori T, Locke F, Mishra A, Perez L, Ayala E, Kharfan-Dabaja M, Nieder M, Fernandez H, Anasetti C, Pidala J. Predictors of overall survival among patients treated with sirolimus/tacrolimus vs methotrexate/tacrolimus for GvHD prevention. Bone Marrow Transplant. 2017 Jul.52(7):1003-1009. Pubmedid: 28368376. Pmcid: PMC7771296.
  • Perez LE, Fernandez H, Ayala E, Beato F, Neuger A, Pidala J, Schell MJ, Anasetti C. Visilizumab with tacrolimus and methotrexate for GvHD prevention after allogeneic hematopoietic cell transplantation from mismatched unrelated donors. Bone Marrow Transplant. 2017 Apr.52(4):627-629. Pubmedid: 27991896. Pmcid: PMC5382111.
  • Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, Maziarz RT, Warlick ED, Fernandez HF, Alyea EP, Hamadani M, Bashey A, Giralt S, Geller NL, Leifer E, Le-Rademacher J, Mendizabal AM, Horowitz MM, Deeg HJ, Horwitz ME. Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. J Clin Oncol. 2017 Apr.35(11):1154-1161. Pubmedid: 28380315. Pmcid: PMC5455603.
  • Luskin MR, Lee JW, Fernandez HF, Abdel-Wahab O, Bennett JM, Ketterling RP, Lazarus HM, Levine RL, Litzow MR, Paietta EM, Patel JP, Racevskis J, Rowe JM, Tallman MS, Sun Z, Luger SM. Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. Blood. 2016 Mar.127(12):1551-1558. Pubmedid: 26755712. Pmcid: PMC4807422.
  • Luskin MR, Gimotty PA, Smith C, Loren AW, Figueroa ME, Harrison J, Sun Z, Tallman MS, Paietta EM, Litzow MR, Melnick AM, Levine RL, Fernandez HF, Luger SM, Carroll M, Master SR, Wertheim GB. A clinical measure of DNA methylation predicts outcome in de novo acute myeloid leukemia. JCI Insight. 2016 Jun.1(9). Pubmedid: 27446991. Pmcid: PMC4951094.
  • Cessna JM, Jim HS, Sutton SK, Asvat Y, Small BJ, Salsman JM, Zachariah B, Fishman M, Field T, Fernandez H, Perez L, Jacobsen PB. Evaluation of the psychometric properties of the PROMIS Cancer Fatigue Short Form with cancer patients. J Psychosom Res. 2016 Feb.81:9-13. Pubmedid: 26800633. Pmcid: PMC4822706.
  • Srikumar T, Markow M, Centeno B, Hoffe S, Tao J, Fernandez H, Strosberg J, Shibata D. Synchronous rectal adenocarcinoma and splenic marginal zone lymphoma. Curr Oncol. 2016 Feb.23(1):e70-e74. Pubmedid: 26966416. Pmcid: PMC4754072.
  • Pasquini MC, Le-Rademacher J, Zhu X, Artz A, DiPersio J, Fernandez HF, Mineishi S, Kamishohara M, Mehta J, Nakamura Y, Ratanatharathorn V, Sobecks R, Burkart J, Bredeson C. Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies. Biol Blood Marrow Tr. 2016 Aug.22(8):1424-1430. Pubmedid: 27154848. Pmcid: PMC4949158.
  • Fernandez HF. What Is the Optimal Induction Therapy for Younger Fit Patients With AML?. Curr Hematol Malig Rep. 2016 10.11(5):327-332. Pubmedid: 27475430.
  • Tees MT, Betts B, Hillgruber R, Ayala E, Field T, Kharfan-Dabaja MA, Locke F, Mishra A, Nishihori T, Ochoa-Bayona JL, Perez L, Pidala J, Anasetti C, Fernandez H, Riches ML. New sources for argument: do HLA-C and HLA disparity in adult double umbilical cord blood transplants predict outcomes?. Bone Marrow Transplant. 2016 09.51(9):1256-1258. Pubmedid: 27088383.
  • Walter RB, Othus M, Paietta EM, Racevskis J, Fernandez HF, Lee JW, Sun Z, Tallman MS, Patel J, Gönen M, Abdel-Wahab O, Levine RL, Estey EH. Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia. Leukemia. 2015 Oct.29(10):2104-2107. Pubmedid: 25772026. Pmcid: PMC4573365.
  • Nelson R, Shapiro JF, Perkins JB, Kim J, Nishihori T, Pidala J, Ayala E, Locke FL, Field T, Mishra A, Riches M, Betts B, Perez L, Yue B, Ochoa-Bayona JL, Alsina M, Fernandez H, Anasetti C, Kharfan-Dabaja MA. Sirolimus, tacrolimus and antithymocyte globulin as GVHD prophylaxis in HLA-mismatched unrelated donor hematopoietic cell transplantation: a single institution experience. Bone Marrow Transplant. 2015 Nov.50(11):1487-1489. Pubmedid: 26301969. Pmcid: PMC4863975.
  • Park SM, Gönen M, Vu L, Minuesa G, Tivnan P, Barlowe TS, Taggart J, Lu Y, Deering RP, Hacohen N, Figueroa ME, Paietta E, Fernandez HF, Tallman MS, Melnick A, Levine R, Leslie C, Lengner CJ, Kharas MG. Musashi2 sustains the mixed-lineage leukemia-driven stem cell regulatory program. J Clin Invest. 2015 Mar.125(3):1286-1298. Pubmedid: 25664853. Pmcid: PMC4362230.
  • Pidala J, Kim J, Betts BC, Alsina M, Ayala E, Fernandez HF, Field T, Kharfan-Dabaja MA, Locke FL, Mishra A, Nishihori T, Ochoa-Bayona L, Perez L, Riches M, Anasetti C. Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial results. Biol Blood Marrow Tr. 2015 Jun.21(6):1074-1082. Pubmedid: 25805300. Pmcid: PMC5757506.
  • Fernandez HF. Beyond the first glance: anthracyclines in AML. Blood. 2015 Jun.125(25):3828-3829. Pubmedid: 26089377.
  • Fernandez HF. Allogeneic Transplantation for Unfavorable-Risk Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2015 Jun.15 Suppl:S70-S72. Pubmedid: 26297283.
  • Pidala J, Kim J, Alsina M, Ayala E, Betts BC, Fernandez HF, Field T, Jim H, Kharfan-Dabaja MA, Locke FL, Mishra A, Nishihori T, Ochoa-Bayona L, Perez L, Riches M, Anasetti C. Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease. Haematologica. 2015 Jul.100(7):970-977. Pubmedid: 25840599. Pmcid: PMC4486232.
  • Nishihori T, Perkins J, Mishra A, Komrokji R, Kim J, Kharfan-Dabaja MA, Perez L, Lancet J, Fernandez H, List A, Anasetti C, Field T. Pretransplantation 5-azacitidine in high-risk myelodysplastic syndrome. Biol Blood Marrow Tr. 2014 Jun.20(6):776-780. Pubmedid: 24534108.
  • Kunter G, Perkins JB, Pidala J, Nishihori T, Kharfan-Dabaja MA, Field T, Fernandez H, Perez L, Locke F, Ayala E, Tomblyn M, Ochoa-Bayona JL, Betts B, Nieder M, Anasetti C. Pharmacokinetically-targeted BU and fludarabine as conditioning before allogeneic hematopoietic cell transplantation for adults with ALL in first remission. Bone Marrow Transplant. 2014 Jan.49(1):11-16. Pubmedid: 23995098.
  • Watts JM, Wang XV, Litzow MR, Luger SM, Lazarus HM, Cassileth PA, Fernandez HF, Douer D, Zickl L, Paietta E, Rowe JM, Tallman MS. Younger adults with acute myeloid leukemia in remission for ≥ 3 years have a high likelihood of cure: The ECOG experience in over 1200 patients. Leuk Res. 2014 Aug.38(8):901-906. Pubmedid: 24986381. Pmcid: PMC4326112.
  • Jaglal MV, Duong VH, Bello CM, Al Ali NH, Padron E, Fernandez HF, List AF, Lancet JE, Komrokji RS. Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure. Leuk Res. 2014 Apr.38(4):443-446. Pubmedid: 24439565.
  • Kharfan-Dabaja MA, Hamadani M, Reljic T, Pyngolil R, Komrokji RS, Lancet JE, Fernandez HF, Djulbegovic B, Kumar A. Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis. Brit J Haematol. 2013 Nov.163(3):315-325. Pubmedid: 24033280.
  • Pidala J, Kim J, Schell M, Lee SJ, Hillgruber R, Nye V, Ayala E, Alsina M, Betts B, Bookout R, Fernandez HF, Field T, Locke FL, Nishihori T, Ochoa JL, Perez L, Perkins J, Shapiro J, Tate C, Tomblyn M, Anasetti C. Race/ethnicity affects the probability of finding an HLA-A, -B, -C and -DRB1 allele-matched unrelated donor and likelihood of subsequent transplant utilization. Bone Marrow Transplant. 2013 Mar.48(3):346-350. Pubmedid: 22863723. Pmcid: PMC4500122.
  • Dinardo CD, Propert KJ, Loren AW, Paietta E, Sun Z, Levine RL, Straley KS, Yen K, Patel JP, Agresta S, Abdel-Wahab O, Perl AE, Litzow MR, Rowe JM, Lazarus HM, Fernandez HF, Margolis DJ, Tallman MS, Luger SM, Carroll M. Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood. 2013 Jun.121(24):4917-4924. Pubmedid: 23641016. Pmcid: PMC3682342.
  • Kharfan-Dabaja MA, Anasetti C, Fernandez HF, Perkins J, Ochoa-Bayona JL, Pidala J, Perez LE, Ayala E, Field T, Alsina M, Nishihori T, Locke F, Pinilla-Ibarz J, Tomblyn M. Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting. Biol Blood Marrow Tr. 2013 Jul.19(7):1087-1093. Pubmedid: 23632090. Pmcid: PMC4667782.
  • Diab A, Zickl L, Abdel-Wahab O, Jhanwar S, Gulam MA, Panageas KS, Patel JP, Jurcic J, Maslak P, Paietta E, Mangan JK, Carroll M, Fernandez HF, Teruya-Feldstein J, Luger SM, Douer D, Litzow MR, Lazarus HM, Rowe JM, Levine RL, Tallman MS. Acute myeloid leukemia with translocation t(8;16) presents with features which mimic acute promyelocytic leukemia and is associated with poor prognosis. Leuk Res. 2013 Jan.37(1):32-36. Pubmedid: 23102703. Pmcid: PMC5382928.
  • Akalin A, Garrett-Bakelman FE, Kormaksson M, Busuttil J, Zhang L, Khrebtukova I, Milne TA, Huang Y, Biswas D, Hess JL, Allis CD, Roeder RG, Valk PJ, Löwenberg B, Delwel R, Fernandez HF, Paietta E, Tallman MS, Schroth GP, Mason CE, Melnick A, Figueroa ME. Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia. PLoS Genet. 2012 Sep.8(6):e1002781. Pubmedid: 22737091. Pmcid: PMC3380828.
  • Gönen M, Sun Z, Figueroa ME, Patel JP, Abdel-Wahab O, Racevskis J, Ketterling RP, Fernandez H, Rowe JM, Tallman MS, Melnick A, Levine RL, Paietta E. CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900. Blood. 2012 Sep.120(11):2297-2306. Pubmedid: 22855599. Pmcid: PMC3447784.
  • Patel JP, Gönen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, Van Vlierberghe P, Dolgalev I, Thomas S, Aminova O, Huberman K, Cheng J, Viale A, Socci ND, Heguy A, Cherry A, Vance G, Higgins RR, Ketterling RP, Gallagher RE, Litzow M, van den Brink MR, Lazarus HM, Rowe JM, Luger S, Ferrando A, Paietta E, Tallman MS, Melnick A, Abdel-Wahab O, Levine RL. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012 Mar.366(12):1079-1089. Pubmedid: 22417203. Pmcid: PMC3545649.
  • Nishihori T, Alekshun TJ, Shain K, Sullivan DM, Baz R, Perez L, Pidala J, Kharfan-Dabaja MA, Ochoa-Bayona JL, Fernandez HF, Yarde DN, Oliveira V, Fulp W, Han G, Kim J, Chen DT, Raychaudhuri J, Dalton W, Anasetti C, Alsina M. Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma. Brit J Haematol. 2012 Jun.157(5):553-563. Pubmedid: 22449149. Pmcid: PMC4030553.
  • Perkins JB, Kim J, Anasetti C, Fernandez HF, Perez LE, Ayala E, Kharfan-Dabaja MA, Tomblyn MR, Sullivan DM, Pidala JA, Field TL. Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. Biol Blood Marrow Tr. 2012 Jul.18(7):1099-1107. Pubmedid: 22198540.
  • Perkins JB, Shapiro JF, Bookout RN, Yee GC, Anasetti C, Janssen WE, Fernandez HF. Retrospective comparison of filgrastim plus plerixafor to other regimens for remobilization after primary mobilization failure: clinical and economic outcomes. Am J Hematol. 2012 Jul.87(7):673-677. Pubmedid: 22674468.
  • Cortes J, Kantarjian H, Ball ED, Dipersio J, Kolitz JE, Fernandez HF, Goodman M, Borthakur G, Baer MR, Wetzler M. Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia. Cancer. 2012 Jan.118(2):418-427. Pubmedid: 21717444. Pmcid: PMC4977021.
  • Padron E, Fernandez H. Anthracycline dose intensification in young adults with acute myeloid leukemia. Ther Adv Hematol. 2012 Feb.3(1):17-27. Pubmedid: 23556109. Pmcid: PMC3573430.
  • Janssen WE, Rahn D, Hackett M, Coyle D, Tomblyn M, Smilee RC, Anasetti C, Fernandez HF. Apheresis and transplant of hematopoietic progenitor cells (HPC) from allogeneic donors of age above 60 years. Bone Marrow Transplant. 2012 Dec.47(12):1520-1525. Pubmedid: 22562079.
  • Pidala J, Kim J, Jim H, Kharfan-Dabaja MA, Nishihori T, Fernandez HF, Tomblyn M, Perez L, Perkins J, Xu M, Janssen WE, Veerapathran A, Betts BC, Locke FL, Ayala E, Field T, Ochoa L, Alsina M, Anasetti C. A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. Haematologica. 2012 Dec.97(12):1882-1889. Pubmedid: 22689677. Pmcid: PMC3590095.
  • Barreyro L, Will B, Bartholdy B, Zhou L, Todorova TI, Stanley RF, Ben-Neriah S, Montagna C, Parekh S, Pellagatti A, Boultwood J, Paietta E, Ketterling RP, Cripe L, Fernandez HF, Greenberg PL, Tallman MS, Steidl C, Mitsiades CS, Verma A, Steidl U. Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. Blood. 2012 Aug.120(6):1290-1298. Pubmedid: 22723552. Pmcid: PMC3418722.
  • Pidala J, Tomblyn M, Nishihori T, Field T, Ayala E, Perkins J, Fernandez H, Locke F, Perez L, Ochoa JL, Alsina M, Anasetti C. Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoids. Haematologica. 2011 Sep.96(9):1351-1356. Pubmedid: 21565902. Pmcid: PMC3166106.
  • Santarone S, Pidala J, Di Nicola M, Field T, Alsina M, Ayala E, Janssen W, Kharfan-Dabaja MA, Ochoa L, Perez L, Perkins J, Raychaudhuri J, Fernandez H, Anasetti C. Fludarabine and pharmacokinetic-targeted busulfan before allografting for adults with acute lymphoid leukemia. Biol Blood Marrow Tr. 2011 Oct.17(10):1505-1511. Pubmedid: 21385623.
  • Perkins J, Field T, Kim J, Kharfan-Dabaja MA, Ayala E, Perez L, Fernandez H, Fancher K, Tate C, Shaw LM, Milone MC, Gardiner JA, Miller S, Anasetti C. Pharmacokinetic targeting of i.v. BU with fludarabine as conditioning before hematopoietic cell transplant: the effect of first-dose area under the concentration time curve on transplant-related outcomes. Bone Marrow Transplant. 2011 Nov.46(11):1418-1425. Pubmedid: 21132026.
  • Pidala J, Kim J, Anasetti C, Kharfan-Dabaja MA, Field T, Perkins J, Ayala E, Perez L, Fernandez H. Targeted i.v. BU and fludarabine (t-i.v. BU/Flu) provides effective control of AML in adults with reduced toxicity. Bone Marrow Transplant. 2011 May.46(5):641-649. Pubmedid: 20711242. Pmcid: PMC5726256.
  • Fernandez HF, Sun Z, Litzow MR, Luger SM, Paietta EM, Racevskis J, Dewald G, Ketterling RP, Rowe JM, Lazarus HM, Tallman MS. Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin. Blood. 2011 May.117(20):5306-5313. Pubmedid: 21415269. Pmcid: PMC3109705.
  • Kharfan-Dabaja MA, Chavez JC, Yu D, Zhu W, Fernandez-Vertiz EI, Perkins J, Shapiro J, Bookout R, Perez L, Fernandez HF, Komrokji RS, Lancetf J, Brand L, Field T, Ayala E, Janssen W, List AF, Anasetti C. Severe hypoalbuminemia at day 90 predicts worse nonrelapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Tr. 2011 Mar.17(3):384-393. Pubmedid: 20655389.
  • Price SL, Lancet JE, George TJ, Wetzstein GA, List AF, Ho VQ, Fernandez HF, Pinilla-Ibarz J, Kharfan-Dabaja MA, Komrokji RS. Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens. Leuk Res. 2011 Mar.35(3):301-304. Pubmedid: 21109304.
  • Nishihori T, Fernandez HF, Coppola D, Ochoa-Bayona JL, Lancet JE, Komrokji RS, Kharfan-Dabaja MA. Hepatobiliary manifestations of acute myeloid leukemia. Leuk Res. 2011 Jun.35(6):e81-e83. Pubmedid: 21232795.
  • Pidala J, Kim J, Kharfan-Dabaja MA, Nishihori T, Field T, Perkins J, Perez L, Fernandez H, Anasetti C. Dysglycemia following glucocorticoid therapy for acute graft-versus-host disease adversely affects transplantation outcomes. Biol Blood Marrow Tr. 2011 Feb.17(2):239-248. Pubmedid: 20637884. Pmcid: PMC5726258.
  • Pidala J, Roman-Diaz J, Kim J, Nishihori T, Perkins J, Tate C, Ochoa-Bayona JL, Field T, Fernandez HF, Tomblyn M, Ayala E, Anasetti C, Kharfan-Dabaja MA. Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complications. Int J Hematol. 2011 Feb.93(2):206-212. Pubmedid: 21246311. Pmcid: PMC5718616.
  • Pidala J, Tomblyn M, Nishihori T, Ayala E, Field T, Fernandez H, Perez L, Locke F, Alsina M, Ochoa JL, Perkins J, Tate C, Shapiro J, Conwell M, Bookout R, Anasetti C. ATG prevents severe acute graft-versus-host disease in mismatched unrelated donor hematopoietic cell transplantation. Biol Blood Marrow Tr. 2011 Aug.17(8):1237-1244. Pubmedid: 21215811. Pmcid: PMC5735843.
  • Pidala J, Kim J, Anasetti C, Kharfan-Dabaja MA, Nishihori T, Field T, Perkins J, Perez L, Fernandez HF. Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia. J Hematol Oncol. 2010 Oct.3:36. Pubmedid: 20925957. Pmcid: PMC2958877.
  • Nishihori T, Perkins J, Kim J, Field T, Pidala J, Roman-Diaz J, Komrokji RS, Fernandez HF, Anasetti C, Kharfan-Dabaja MA. Allogeneic hematopoietic cell transplantation for myelofibrosis: a 10-year experience at single institution. Am J Hematol. 2010 Nov.85(11):904-907. Pubmedid: 20890908.
  • Pidala J, Kim J, Perkins J, Field T, Fernandez H, Perez L, Ayala E, Kharfan-Dabaja M, Anasetti C. Mycophenolate mofetil for the management of steroid-refractory acute graft vs host disease. Bone Marrow Transplant. 2010 May.45(5):919-924. Pubmedid: 19767783.
  • Fernandez HF, Rowe JM. Induction therapy in acute myeloid leukemia: intensifying and targeting the approach. Curr Opin Hematol. 2010 Mar.17(2):79-84. Pubmedid: 20087177.
  • Perkins J, Field T, Kim J, Kharfan-Dabaja MA, Fernandez H, Ayala E, Perez L, Xu M, Alsina M, Ochoa L, Sullivan D, Janssen W, Anasetti C. A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis. Biol Blood Marrow Tr. 2010 Jul.16(7):937-947. Pubmedid: 20102746.
  • Field T, Perkins J, Huang Y, Kharfan-Dabaja MA, Alsina M, Ayala E, Fernandez HF, Janssen W, Lancet J, Perez L, Sullivan D, List A, Anasetti C. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2010 Feb.45(2):255-260. Pubmedid: 19543327.
  • Fonseca R, Richardson P, Giralt S, Lonial S, Rajkumar SV, Stewart AK, Bensinger W, Somlo G, Vescio R, Mikhael J, Reeder C, Tiedemann R, Tricot G, Rifkin R, Shaughnessy J, Munshi N, Raje N, Ghobrial I, Laubach J, Schlossman R, Treon S, Mahindra A, Avigan D, Rosenblatt J, Jagannath S, Niesvizky R, Landau H, Chen-Kiang S, Siegel DS, Zimmerman T, Mehta J, Vesole D, Rosen S, Hofmeister C, Lacy M, Dispenzieri A, Borrello I, Hayman SR, Kumar S, Buadi F, Dingli D, Russell S, Alsina MA, Fernandez H, Roy V, Pereira D, Stadtmauer E, Vij R, Jakubowiak A, Lentzsch S, Song K, Trudel S, Chen C, Reece D, Stewart D, Singhal S, Comenzo R, Gertz MA, Greipp PR, Durie B, Barlogie B, Anderson K, Dalton W, Coleman M, Novis S, Kyle RA. Conflicts of interest, authorship, and disclosures in industry-related scientific publications. Mayo Clin Proc. 2010 Feb.85(2):197-199. Pubmedid: 20118399. Pmcid: PMC2813833.
  • Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, Tallman MS, Sun Z, Wolniak K, Peeters JK, Liu W, Choe SE, Fantin VR, Paietta E, Löwenberg B, Licht JD, Godley LA, Delwel R, Valk PJ, Thompson CB, Levine RL, Melnick A. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010 Dec.18(6):553-567. Pubmedid: 21130701. Pmcid: PMC4105845.
  • Hoda D, Pidala J, Salgado-Vila N, Kim J, Perkins J, Bookout R, Field T, Perez L, Ayala E, Ochoa-Bayona JL, Raychaudhuri J, Alsina M, Greene J, Janssen W, Fernandez HF, Anasetti C, Kharfan-Dabaja MA. Sirolimus for treatment of steroid-refractory acute graft-versus-host disease. Bone Marrow Transplant. 2010 Aug.45(8):1347-1351. Pubmedid: 19966849.
  • Fernandez HF. New trends in the standard of care for initial therapy of acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2010.2010:56-61. Pubmedid: 21239771.
  • Pidala J, Kim J, Field T, McBride A, Kharfan-Dabaja M, Perkins J, Fernandez H, Perez L, Ayala E, Anasetti C. Infliximab for managing steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Tr. 2009 Sep.15(9):1116-1121. Pubmedid: 19660725.
  • Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, Racevskis J, Dewald GW, Ketterling RP, Bennett JM, Rowe JM, Lazarus HM, Tallman MS. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009 Sep.361(13):1249-1259. Pubmedid: 19776406. Pmcid: PMC4480917.
  • Escalón MP, Stefanovic A, Venkatraman A, Pereira D, Santos ES, Goodman M, Byrnes JJ, Fernandez HF. Autologous transplantation for relapsed non-Hodgkin's lymphoma using intravenous busulfan and cyclophosphamide as conditioning regimen: a single center experience. Bone Marrow Transplant. 2009 Jul.44(2):89-96. Pubmedid: 19169287.
  • Fernandez HF, Kharfan-Dabaja MA. Tyrosine kinase inhibitors and allogeneic hematopoietic cell transplantation for chronic myeloid leukemia: targeting both therapeutic modalities. Cancer Control. 2009 Apr.16(2):153-157. Pubmedid: 19337201.
  • Abou Mourad YR, Fernandez HF, Kharfan-Dabaja MA. Allogeneic hematopoietic cell transplantation for adult Philadelphia-positive acute lymphoblastic leukemia in the era of tyrosine kinase inhibitors. Biol Blood Marrow Tr. 2008 Sep.14(9):949-958. Pubmedid: 18721758.
  • Kharfan-Dabaja M, Abou Mourad Y, Fernandez H, Pasquini M, Santos E. Hematopoietic cell transplantation in acute promyelocytic leukemia: a comprehensive review. Biol Blood Marrow Tr. 2007 Sep.13(9):997-1004. Pubmedid: 17697961.
  • Fernandez H, Escalon M, Pereira D, Lazarus H. Autotransplant conditioning regimens for aggressive lymphoma: are we on the right road?. Bone Marrow Transplant. 2007 Sep.40(6):505-513. Pubmedid: 17589535.
  • Vance G, Kim H, Hicks G, Cherry A, Higgins R, Hulshizer R, Tallman M, Fernandez H, Dewald G. Utility of interphase FISH to stratify patients into cytogenetic risk categories at diagnosis of AML in an Eastern Cooperative Oncology Group (ECOG) clinical trial (E1900). Leuk Res. 2007 May.31(5):605-609. Pubmedid: 16996130.
  • Santos E, Goodman M, Byrnes J, Fernandez H. Thalidomide effects in the post-transplantation setting in patients with multiple myeloma. Hematology. 2004 Feb.9(1):35-39. Pubmedid: 14965866.
  • Chen M, Fernandez HL. Stimulation of beta-amyloid precursor protein alpha-processing by phorbol ester involves calcium and calpain activation. Biochem Bioph Res Co. 2004 Apr.316(2):332-340. Pubmedid: 15020222.
  • Andersson BS, Kashyap A, Couriel D, Madden T, de Lima M, Thall PF, Fernandez H, Vaughan WP, Jones R, Wingard JR, Blume KG, Champlin RE. Intravenous busulfan in pretransplant chemotherapy: bioavailability and patient benefit. Biol Blood Marrow Tr. 2003 Nov.9(11):722-724. Pubmedid: 14682302.
  • Kharfan-Dabaja M, Morgensztern D, Santos E, Goodman M, Fernandez H. Acute graft-versus-host disease (aGVHD) presenting with an acquired lupus anticoagulant. Bone Marrow Transplant. 2003 Jan.31(2):129-131. Pubmedid: 12621495.
  • Bahlis N, McCafferty-Grad J, Jordan-McMurry I, Neil J, Reis I, Kharfan-Dabaja M, Eckman J, Goodman M, Fernandez H, Boise L, Lee K. Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin Cancer Res. 2002 Dec.8(12):3658-3668. Pubmedid: 12473574.
  • Andersson B, Kashyap A, Gian V, Wingard J, Fernandez H, Cagnoni P, JonesRB, Tarantolo S, Hu W, Blume K, Forman S, Champlin R. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Tr. 2002.8(3):145-154. Pubmedid: 11939604.
  • Fernandez H, Tran H, Albrecht F, Lennon S, Caldera H, Goodman M. Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation. Biol Blood Marrow Tr. 2002.8(9):486-492. Pubmedid: 12374453.
  • Kashyap A, Wingard J, Cagnoni P, Roy J, Tarantolo S, Hu W, Blume K, NilandJ, Palmer J, Vaughan W, Fernandez H, Champlin R, Forman S, Andersson B. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mo. Biol Blood Marrow Tr. 2002.8(9):493-500. Pubmedid: 12374454.
  • Santiago S, Misiakos E, De Faria W, Salgar S, Gandia C, Feo C, Berho M, Ruiz P, Fernandez H, Ricordi C, Miller J, Tzakis A. Sternum transplantation: a novel therapy for aplastic anemia in a rat model. Transplant Proc. 2001 Jun.33(4):2600-2602. Pubmedid: 11406258.
  • Andersson B, Gajewski J, Donato M, Giralt S, Gian V, Wingard J, TarantoloS, Fernandez H, Hu W, Blume K, Kashyap A, Forman S, Champlin R. Allogeneic stem cell transplantation (BMT) for AML and MDS following i.v. busulfan and cyclophosphamide (i.v. BuCy). Bone Marrow Transplant. 2000 May.25:S35-S38. Pubmedid: 10933185.
  • Krishan A, Sridhar K, Mou C, Stein W, Lyubimov E, Hu Y, Fernandez H. Synergistic effect of prochlorperazine and dipyridamole on the cellular retention and cytotoxicity of doxorubicin. Clin Cancer Res. 2000 Apr.6(4):1508-1517. Pubmedid: 10778983.
  • Restrepo A, Albrecht F, Raez L, Fernandez H, Nassiri M, Byrne G J, Cassileth P. Post-liver transplantation lymphoproliferative disorders with and without infusions of donor bone marrow cells. Crit Rev Oncog. 1999 Sep.10(3):239-245. Pubmedid: 10468183.
  • Koya R, Andersen J, Fernandez H, Goodman M, Spector N, Smith R, Hanlon J, Cassileth P. Analysis of the value of empiric vancomycin administration in febrile neutropenia occurring after autologous peripheral blood stem cell transplants. Bone Marrow Transplant. 1998 May.21(9):923-926. Pubmedid: 9613785 .
  • Morrell L, Lee Y, Hurley J, Arias M, Mies C, Richman S, Fernandez H, Donofrio K, Raub WA J, Cassileth P. A Phase II trial of neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of patients with locally advanced breast carcinoma. Cancer. 1998 Feb.82(3):503-511. Pubmedid: 9452268 .
  • Schenkein D, Roitman D, Miller K, Morelli J, Stadtmauer E, Pecora A, Cassileth P, Fernandez H, Cooper B, Kutteh L, Lazarus H. A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphoma. Biol Blood Marrow Tran. 1997 Oct.3(4):210-216. Pubmedid: 9360783 .
  • Garcia-Morales R, Esquenazi V, Carreno M, Karatzas T, Gomez C, Cirocco R, Zucker K, Fuller L, Alamo A, Temple D, Fernandez H, Ciancio G, Burke G 3rd, WebbM, Nery J, Roth D, Ricordi C, Tzakis A, Miller J. PCR-flow analysis used to detect the levels of chimerism in peripheral blood of bone-marrow infused organ allograft recipients at the time of rejection episodes. Transplant Proc. 1997 Jun.29(4):2179-2180. Pubmedid: 9193578 .
  • Ricordi C, Karatzas T, Nery J, Webb M, Selvaggi G, Fernandez L, Khan F, Ruiz P, Schiff E, Olson L, Fernandez H, Bean J, Esquenazi V, Miller J, TzakisAG. High-dose donor bone marrow infusions to enhance allograft survival: the effect of timing. Transplantation. 1997 Jan.63(1):7-11. Pubmedid: 9000653 .
  • Garcia-Morales R, Esquenazi V, Zucker K, Gomez C, Fuller L, Carreno M, Cirocco R, Alamo A, Karatzas T, Burke GW 3rd, Ciancio G, Temple D, Fernandez H, Ricordi C, Tzakis A, Miller J. Assessment of the effects of cadaveric donor bone marrow on chimerism in kidney transplant recipients by the polymerase chain reaction-flow technique. Transplant Proc. 1997 Feb.29(1-2):1219-1221. Pubmedid: 9123282 .
  • Reik RA, Noto TA, Fernandez HF. Safety of large-volume leukapheresis for collection of peripheral blood progenitor cells. J Clin Apher. 1997 Dec.12(1):10-13. Pubmedid: 9097229.
  • Reik R, Noto T, Fernandez H. Safety of large-volume leukapheresis for collection of peripheral blood progenitor cells. J Clin Apher. 1997.12(1):10-13. Pubmedid: 9097229 .
  • Garcia-Morales R, Esquenazi V, Zucker K, Gomez C, Fuller L, Carreno M, Cirocco R, Alamo A, Karatzas T, Burke GW 3rd, Ciancio G, Temple D, Fernandez H, Ricordi C, Tzakis A, Miller J. An assessment of the effects of cadaver donor bone marrow on kidney allograft recipient blood cell chimerism by a novel technique combining PCR and flow cytometry. Transplantation. 1996 Oct.62(8):1149-1160. Pubmedid: 8900317 .
  • Ricordi C, Karatzas T, Selvaggi G, Neri J, Fernandez H, Ruiz M, LinetskyE, Kong S, Webb M, Bottino R, et a. Enhanced allograft acceptance by multiple infusions of donor bone marrow in humans. Transplant Proc. 1995 Dec.27(6):3381-3381. Pubmedid: 8540006 .
  • Ricordi C, Karatzas T, Selvaggi G, Nery J, Webb M, Fernandez H, Ruiz P, Kong S, Esquenazi V, Miller J, et a. Multiple bone marrow infusions to enhance acceptance of allografts from the same donor. Ann N Y Acad Sci. 1995 Dec.770:345-350. Pubmedid: 8597372 .
  • Ucar A, Fernandez H, Byrnes J, Lian E, Harrington WJ J. Thrombotic microangiopathy and retroviral infections: a 13-year experience. Am J Hematol. 1994 Apr.45(4):304-309. Pubmedid: 7909982 .

Patient Comments
Overall Satisfaction
0
★★★★★
★★★★★

0 patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments